Large-Scale In Vitro and In Vivo CRISPR-Cas9 Knockout Screens Identify a 16-Gene Fitness Score for Improved Risk Assessment in Acute Myeloid Leukemia.

Peng Jin Qiqi Jin Xiaoling Wang Ming Zhao Fangyi Dong Ge Jiang Zeyi Li Jie Shen Wei Zhang Shishuang Wu Ran Li Yunxiang Zhang Xiaoyang Li Junmin Li

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Our findings demonstrated the utility of the AFG16 score as a powerful tool for better risk stratification and selecting patients most likely to benefit from chemotherapy and alternative experimental therapies.

Keyphrases

crispr cas
risk assessment
end stage renal disease
genome wide
ejection fraction
newly diagnosed
chronic kidney disease
genome editing
peritoneal dialysis
high throughput
squamous cell carcinoma
copy number
heavy metals
radiation therapy
gene expression
patient reported outcomes
locally advanced
rectal cancer